We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Laboratory Model Reveals Genetic Risk Loci for AMD

By LabMedica International staff writers
Posted on 20 May 2019
Image: A micrograph showing retinal cells derived from a patient\'s skin cells, via induced pluripotent stem cells. The cells are organized in a polygonal shape and have taken on characteristic pigmentation (Photo courtesy of the University of California, San Diego).
Image: A micrograph showing retinal cells derived from a patient\'s skin cells, via induced pluripotent stem cells. The cells are organized in a polygonal shape and have taken on characteristic pigmentation (Photo courtesy of the University of California, San Diego).
Eye disease researchers used advanced stem cell technology to create a laboratory model of age-related macular degeneration (AMD), which enabled in-depth analysis of the genetics underlying the syndrome.

AMD, one of the most common causes of vision loss in the elderly, causes the slow degradation of the cells comprising the macula of the retina, which is the region in the back of the eye that transmits information to the brain. The exact cause of the disease is unknown, but studies have suggested that genetics plays an important role.

To define the role of genetic risk in AMD, investigators at the University of California, San Diego (USA) created an in vitro model based on human induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) cells from six subjects. To do this, they generated iPSCs from skin cells, and then used a cocktail of molecules and growth factors to transform the iPSCs into retinal cells. The induced RPEs were found to have morphological and molecular characteristics similar to those of native RPE.

The model system was used to generate molecular data, including RNA transcripts and epigenetic information. These findings were combined with complementary published data from 18 adults with and without AMD.

Results revealed that the genetic variant most closely associated with AMD was rs943080, a specific genetic variation that affected expression of the VEGFA (vascular endothelial growth factor A) gene, possibly through regulation by a non-coding region of the genome. Five of the six participants had one copy of rs943080 and one person had two copies of the gene variant. VEGFA protein is known for supporting new blood vessel growth, a process that characterizes AMD.

"We did not start with the VEGFA gene when we went looking for genetic causes of AMD," said senior author Dr. Kelly A. Frazer, professor of pediatrics at the University of California, San Diego. "But we were surprised to find that, with samples from just six people, this genetic variation clearly emerged as a causal factor."

The authors concluded that their results had established a molecular hypothesis for the VEGFA genetic risk locus in AMD and illustrated the potential of iPSC-RPE as a model system to study the molecular function of genetic variation associated with AMD.

The AMD stem cell study was published in the May 9, 2019, online edition of the journal Stem Cell Reports.

Related Links:
University of California, San Diego

New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Portable Electronic Pipette
Mini 96
Hemodynamic System Monitor
OptoMonitor
New
Gold Member
Collection and Transport System
PurSafe Plus®

Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more